The new drug from Biogen carries a very hefty price tag along with a very limited level of efficacy that has now been further limited by recent FDA labeling guidelines. The drug that costs $56,000 a year and is delivered intravenously is designed to flatten the slope of cognitive decline and will not reverse memory loss, behavioral challenges or other functional deficits.
The irony is not lost on us that transcranial infrared photobiomodulation, a treatment for which there is published evidence of reversal of memory, mood and motor symptoms and costing less than $4000, has not been afforded much recognition within the mainstream Alzheimer's treatment community. We are hopeful this will changes as clinicians like Dr. Dale Bredesen recognize and advocate for the use of this technology in the treatment of neurodegenerative disorders.
Quietmind Foundation has been selected to partner with Dr. Bredesen's company Apollo Health to provide consultation and training in the clinical use of photobiomodulation with their practitioners and patients. We are excited by this important opportunity and look forward to working with this community of providers and consumers and hope the word will spread and more people will be able to take advantage of this important neurophysiological health resource.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.